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Background: The development of genotyping arrays containing hundreds of thousands of rare variants across the
genome and advances in high-throughput sequencing technologies have made feasible empirical genetic
association studies to search for rare disease susceptibility alleles. As single variant testing is underpowered to
detect associations, the development of statistical methods to combine analysis across variants – so-called “burden
tests” - is an area of active research interest. We previously developed a method, the admixture maximum
likelihood test, to test multiple, common variants for association with a trait of interest. We have extended this
method, called the rare admixture maximum likelihood test (RAML), for the analysis of rare variants. In this paper we
compare the performance of RAML with six other burden tests designed to test for association of rare variants.
Results: We used simulation testing over a range of scenarios to test the power of RAML compared to the other
rare variant association testing methods. These scenarios modelled differences in effect variability, the average
direction of effect and the proportion of associated variants. We evaluated the power for all the different scenarios.
RAML tended to have the greatest power for most scenarios where the proportion of associated variants was small,
whereas SKAT-O performed a little better for the scenarios with a higher proportion of associated variants.
Conclusions: The RAML method makes no assumptions about the proportion of variants that are associated with
the phenotype of interest or the magnitude and direction of their effect. The method is flexible and can be applied
to both dichotomous and quantitative traits and allows for the inclusion of covariates in the underlying regression
model. The RAML method performed well compared to the other methods over a wide range of scenarios.
Generally power was moderate in most of the scenarios, underlying the need for large sample sizes in any form of
association testing.Background
Genome-wide association studies (GWAS) have success-
fully identified common genetic variants, mainly com-
mon single nucleotide polymorphisms (SNP), with small
to modest effects for many complex human diseases and
traits [1]. However, for most diseases common suscepti-
bility variants identified to date explain only a small pro-
portion of the heritable component of disease risk. A
range of genetic models may explain the missing herit-
ability from a very large number of common variants
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reproduction in any medium, provided the orvariants with stronger effects. Rare disease-susceptibility
alleles identified so far have mostly been in the coding
sequence of genes and are associated with higher disease
risks than known common susceptibility alleles.
Until recently a limited understanding of the architec-
ture of rare genetic variation across the genome and lim-
itations of genotyping technologies have restricted the
search for rare disease-susceptibility alleles to the analysis
of a small number of candidate genes for specific diseases.
The development of genotyping arrays containing hun-
dreds of thousands of rare variants across the genome and
advances in high-throughput sequencing technologies
have made feasible empirical genetic association studies to
search for rare disease susceptibility alleles. Even so, stand-
ard methods used for association testing, in whichd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2105/14/177association with the trait of interest is tested one variant
at a time, are limited by statistical power. As a result there
has been an increase in interest in alternative analytic
methods in which the information across multiple variant
sites is combined – for example all variants in a specified
gene or genomic region. Depending on the underlying
model of genetic association these “burden” tests can
enhance statistical power. Examples of these include the
cohort allelic sum test (CAST) [2,3], the combined multi-
variate and collapsing (CMC) test [2], the weighted sum
test (WST) [4], the variable-threshold test (VTT) [5], the
C-alpha test (CAT) [6], the sequence kernel association
test (SKAT) [7,8], and the estimated regression coefficient
(EREC) test [9].
The CAST and CMC methods collapse information on
all rare variants within a region into a single dichoto-
mous variable for each subject and then apply a univariate
test. Rare variants are defined by a fixed threshold for
minor allele frequency. The WST is a non-parametric test
in which rare variants are grouped according to function
(e.g. gene) and each individual is scored by a sum of the
mutation counts weighted by the variance under the null
hypothesis. The VT approach selects an allele frequency
threshold by maximising the test statistic over all thresh-
olds and assesses statistical significance by permutation.
The major limitation of these simple burden tests is that
they do not account for the direction of effects of the
functional alleles that are assumed to be the same. How-
ever, a gene harbouring phenotypically relevant variation
could include a handful of rare Mendelian mutations that
cause disease, some variants that moderately increase or
decrease risk, along with numerous variants of no effect.
The CAT contrasts the variance of each observed count
with the expected variance. However, the method does
not allow for covariate adjustment. SKAT is a score-based
variance-component test that makes no assumption about
directionality of effect by performing multiple regressions
of a phenotype on genotype for all variants in a region [7].
P-values are calculated analytically. The most recent
implementation, called SKAT-O is a generalisation of the
C-alpha test that enables the incorporation of covariates
and is more powerful than simple burden tests over a
range of plausible genetic models [8]. The EREC test is a
modification of the WST and VTT in which the weighting
is based on the estimated regression coefficient.
We have previously developed an admixture maximum
likelihood (AML) test to test for association of multiple
common genetic variants with the trait of interest [10].
The method is flexible and can be applied to both disease
and quantitative traits and can include covariates. In this
paper we propose an extension of the AML test, hereafter
called RAML (rare admixture maximum likelihood test),
for the analysis of uncommon variants. RAML takes ac-
count of variants that increase or decrease risk or have noeffect on risk. We have compared the performance of
RAML with SKAT-O and with five tests implemented by
Score-SEQ (two fixed threshold methods with the minor
allele frequency threshold set to 1 percent and 5 percent,
a modified WST, a modified VTT and the EREC test) [9].
Methods
The RAML method provides an omnibus test for joint
effects of multiple variants on a phenotype and formu-
lates the alternative hypothesis in terms of the probabil-
ity that a given variant is associated with disease (α), the
average effect of the associated variants (η) and the
expected standard error of this effect (σ). The effect of
each variant is estimated as the signed z-statistic (Z)
from the score test. To generate the omnibus test statis-
tic the distribution of the effects under the alternative
hypothesis need to be defined. It is desirable to use a
distribution with a conjugate prior so that the likelihood
will have a tractable computational form. We defined
this as a normal distribution of the z-statistic. Using the
z-statistic gives flexibility to incorporate covariates and
the approach can be easily extended to quantitative trait
and survival-time analyses. The average expected z-statistic
can be positive or negative corresponding to an excess of
deleterious or protective variants respectively. Given that a
variant is associated with the phenotype the likelihood of
observing the test statistic (Z)
∫p T μ ¼ xÞp μ ¼ x η; σÞdxjðjð ð1Þ
To solve this equation we can think of it in terms of
the sum of two normal distributions x ~ N(0,1) and y ~ N
(μ,σ2). The likelihood of observing S = x + y can then be
expressed as
∫p S y ¼ Y Þp y ¼ Y N μ; σ2 Þdy ð2Þ
The distribution of Z given μ is distributed as a N(0,1)
distribution so it can be seen that equations (1) and (2)
are equivalent. Thus in the case that a variant is associ-
ated the test statistic Z is distributed as N(η,1 + σ2). The
log-likelihood is of the form
l α; η; σð Þ ¼ ∑
i
log 1−αþ αL1i=L0ið Þ ð3Þ
where L1i is the likelihood given the variant is associated
(which will be from a N(η,1 + σ2) distribution) and L0i is
the null likelihood (which is from a N(0,1) distribution).
Thus the log-likelihood can be expressed as
l α; η; σð Þ ¼ ∑
i
log 1−αþ αﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ






 !( ) !
ð4Þ
which we maximised using the Bound Optimization BY
Quadratic Approximation (BOBYQA) algorithm [11].
Table 1 Power (%) of seven methods to detect association of rare variants under seven scenarios for underlying genetic architecture using data simulated for
BRCA1 in 2000 cases and 2000 controls
Threshold for significance
P < 0.001 P < 0.01 P < 0.05
Scenario* Proportion of
variants associated
RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC
1 0.05 5.0 4.5 3.0 2.5 2.0 3.0 3.0 15.0 11.0 10.0 7.5 8.0 7.0 10.0 30.0 29.0 22.5 18.5 20.5 19.5 26.0
2 0.05 5.0 6.5 1.5 2.0 1.0 1.5 3.0 11.5 11.5 4.5 6.0 5.5 9.0 8.0 28.0 21.5 14.5 10.5 13.5 17.0 16.0
3 0.05 7.5 5.0 2.5 0.5 1.5 1.5 4.0 13.5 11.0 7.0 6.0 7.0 7.0 8.0 25.5 26.0 16.0 19.5 17.0 17.5 22.5
4 0.05 7.0 4.0 2.0 1.0 1.0 1.0 2.5 14.0 12.5 5.0 3.5 5.0 4.5 8.0 26.0 23.5 12.5 12.0 9.5 10.0 21.0
5 0.05 6.5 5.0 2.0 2.0 1.5 2.0 3.5 14.5 9.5 5.0 2.5 3.5 5.5 6.5 27.5 18.0 11.5 8.0 10.0 13.5 14.5
6 0.05 9.0 4.5 1.0 0.5 0.5 1.0 3.5 16.0 11.0 5.0 4.0 3.0 3.0 8.5 26.0 20.5 12.5 10.5 11.0 10.5 18.5
7 0.05 8.5 5.0 1.0 1.5 0.5 1.5 4.0 16.0 8.0 3.0 4.0 3.5 4.0 7.5 24.5 21.5 8.0 8.5 6.5 10.0 16.5
1 0.10 7.5 6.0 6.0 2.0 5.0 4.5 5.5 14.5 16.0 11.0 8.0 10.0 11.0 15.0 30.0 30.0 24.5 21.5 20.0 20.5 25.0
2 0.10 2.5 3.5 1.5 2.0 1.5 0.5 1.5 8.5 8.5 6.0 5.5 7.0 6.5 10.5 26.0 24.0 19.5 17.5 17.5 17.5 20.5
3 0.10 4.5 5.0 3.0 2.5 3.0 1.5 3.5 10.5 8.5 7.0 4.5 5.5 7.5 8.5 22.0 19.5 15.0 11.5 14.0 15.5 18.5
4 0.10 3.5 3.0 2.0 2.0 1.5 1.5 2.5 9.5 10.5 6.0 3.0 4.5 3.5 7.5 22.0 18.5 13.5 13.0 13.0 12.5 17.5
5 0.10 4.0 4.5 3.0 1.0 1.5 3.0 2.5 10.5 9.0 5.5 3.0 5.0 5.5 9.0 23.0 21.0 13.0 11.5 14.0 14.5 22.0
6 0.10 2.5 3.5 1.5 1.0 1.5 1.0 1.5 9.0 9.0 5.0 2.5 5.5 3.5 5.5 21.0 18.0 10.0 9.0 9.0 11.0 16.5
7 0.10 4.0 3.0 1.0 1.0 0.5 2.0 3.5 11.0 10.5 2.5 5.0 3.0 3.0 7.5 25.5 20.0 11.5 11.5 12.0 12.5 17.0
1 0.20 6.5 7.5 7.5 4.0 5.5 4.5 7.5 23.5 27.5 23.5 18.5 24.5 20.5 25.5 40.0 44.5 44.0 40.0 44.5 39.0 43.5
2 0.20 4.0 6.5 4.5 2.0 4.5 4.0 4.5 14.0 12.5 14.0 7.0 10.0 9.5 12.5 23.0 26.5 23.5 16.5 22.5 23.0 24.0
3 0.20 5.0 6.0 5.5 3.5 5.0 5.5 5.0 14.5 17.0 15.0 12.5 16.5 13.0 17.0 27.5 36.5 31.0 28.5 34.0 30.0 35.5
4 0.20 2.5 3.0 1.5 1.5 1.5 1.0 2.0 7.5 10.5 5.0 6.5 5.5 5.0 8.0 18.5 21.5 16.0 14.0 16.5 17.0 18.5
5 0.20 4.5 5.0 1.0 1.0 1.5 1.0 2.5 10.5 9.0 7.0 4.0 4.5 6.0 8.0 24.0 25.5 17.5 13.5 15.0 14.5 20.5
6 0.20 0.5 1.0 0.0 0.0 0.5 0.0 0.5 6.5 6.5 3.5 2.5 2.0 1.5 4.5 17.0 20.0 10.0 12.0 11.0 8.5 18.5
7 0.20 3.0 3.5 0.5 0.5 1.0 0.5 0.5 9.0 9.5 3.0 4.0 2.5 3.5 6.5 23.5 21.5 12.0 9.5 12.0 12.0 17.5
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test, T1fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent MAF, WST weighted sum test, VTT variable threshold test,


















Table 2 Power (%) of seven methods to detect association of rare variants under seven scenarios for underlying genetic architecture using data simulated for
BRCA2 in 2000 cases and 2000 controls
Threshold for significance
P < 0.001 P < 0.01 P < 0.05
Scenario* Proportion of
variants associated
RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC
1 0.05 19.5 2.5 0.5 2.5 1.5 4.5 5.5 41.0 7.5 6.0 7.0 6.0 14.5 11.0 57.5 18.0 21.5 15.0 15.5 29.5 18.5
2 0.05 15.5 4.5 1.5 3.0 2.0 3.0 5.0 26.5 9.5 3.0 6.0 7.0 7.5 10.0 44.0 21.0 14.0 15.0 11.5 18.5 18.0
3 0.05 13.0 2.5 0.5 2.0 2.0 2.5 2.5 27.5 4.0 4.0 4.0 2.5 3.5 4.5 45.5 13.5 15.5 8.0 9.0 17.0 11.5
4 0.05 14.0 3.5 1.5 2.5 1.5 3.5 3.0 27.0 9.5 4.0 6.5 6.0 7.5 8.5 39.5 18.5 7.5 13.5 13.5 16.0 16.0
5 0.05 14.5 3.0 0.5 2.0 1.5 2.5 3.5 31.0 8.0 3.0 5.5 3.5 7.0 8.0 47.0 12.5 15.0 10.5 9.0 17.0 13.0
6 0.05 15.0 2.5 0.5 0.5 1.0 1.5 1.0 30.0 9.5 4.0 7.0 7.0 4.0 9.0 45.5 21.0 8.0 17.0 15.0 14.0 21.0
7 0.05 18.0 0.5 0.0 0.5 0.0 1.5 1.5 29.5 2.5 3.0 1.0 1.0 3.0 2.5 44.0 9.0 8.5 5.0 3.5 9.0 10.0
1 0.10 14.5 1.5 3.0 1.5 2.5 7.5 3.5 30.5 8.0 13.0 6.0 8.0 15.5 8.5 48.5 19.0 24.0 14.5 20.5 31.0 20.0
2 0.10 9.5 2.0 1.0 1.5 2.0 3.5 3.0 24.5 10.5 4.5 7.0 7.5 8.5 9.0 40.0 22.0 15.5 18.0 19.5 18.5 23.0
3 0.10 11.5 1.5 1.5 1.0 2.0 3.0 2.5 27.0 5.0 9.0 4.0 4.5 8.5 6.0 41.5 12.5 20.5 10.5 10.5 22.5 13.5
4 0.10 11.0 3.0 2.0 2.5 1.0 2.5 2.5 20.5 7.0 4.0 5.0 3.5 9.5 5.5 39.5 18.0 13.0 11.5 12.5 16.0 14.0
5 0.10 13.5 2.5 3.0 1.5 2.0 3.5 2.5 24.0 6.0 6.0 4.0 3.0 9.0 7.0 40.5 18.0 15.5 12.0 13.5 18.0 14.5
6 0.10 6.5 0.5 0.0 0.0 0.0 0.0 0.5 17.0 4.5 1.0 2.5 3.0 3.0 3.5 36.0 13.0 7.0 7.5 8.5 11.5 10.5
7 0.10 7.5 1.5 1.5 2.0 1.0 3.0 2.0 22.5 4.0 5.0 4.0 4.0 8.0 4.0 40.5 15.5 13.5 9.0 10.5 17.0 13.0
1 0.20 20.0 9.0 12.0 9.5 12.0 22.5 11.0 41.0 18.0 27.0 17.0 25.0 39.5 21.0 59.0 31.5 47.5 28.0 38.0 55.0 30.0
2 0.20 8.5 1.0 2.5 0.5 1.5 4.5 2.5 22.0 5.5 11.0 5.0 8.0 13.5 7.0 45.0 18.5 27.0 12.0 21.5 30.0 17.0
3 0.20 9.0 3.0 5.0 3.0 6.5 9.0 4.0 25.5 9.0 17.5 9.0 13.0 20.0 10.5 44.5 17.0 34.0 16.0 22.0 34.5 19.5
4 0.20 8.5 1.0 1.0 0.5 1.0 1.5 1.0 21.5 6.5 6.0 4.0 6.0 9.0 5.5 38.0 15.0 16.0 13.0 12.0 20.5 17.5
5 0.20 12.5 4.0 2.5 4.0 1.0 4.5 4.0 29.0 8.0 5.5 6.0 6.0 12.5 8.5 43.5 17.5 17.5 14.0 15.0 24.0 18.0
6 0.20 5.5 2.0 1.0 2.5 1.0 2.5 3.0 21.5 4.0 3.0 5.0 3.5 7.0 6.0 35.0 15.5 12.0 10.0 11.0 15.5 15.0
7 0.20 8.5 2.5 1.0 1.5 1.0 1.5 3.0 21.0 6.0 3.0 5.0 5.0 3.5 7.0 42.0 16.5 9.0 13.0 12.5 14.0 16.0
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test, T1 fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent MAF, WST weighted sum test, VTT variable threshold test,


















Table 3 Power (%) of seven methods to detect association of rare variants under seven scenarios for underlying genetic architecture using data simulated for
TERT in 2000 cases and 2000 controls
Threshold for significance
P < 0.001 P < 0.01 P < 0.05
Scenario* Proportion of
variants associated
RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC RAML SKAT-O T1 T5 WST VTT EREC
1 0.05 15.5 10.5 3.5 4.0 4.0 6.5 10.5 34.0 22.5 14.0 16.0 14.5 15.0 20.5 48.5 36.0 25.5 22.5 24.0 30.0 34.0
2 0.05 19.5 13.0 5.0 4.0 3.5 7.0 13.5 28.5 21.5 11.5 11.0 12.0 14.5 19.0 42.5 38.5 24.0 21.5 24.0 25.0 36.5
3 0.05 18.0 10.5 6.5 4.5 3.5 5.5 6.5 33.5 17.5 12.5 7.0 11.0 12.0 18.5 47.0 35.5 26.0 18.0 25.0 25.5 33.5
4 0.05 13.0 5.0 2.0 1.0 1.0 1.0 3.0 22.5 13.5 7.0 4.0 5.0 6.0 9.0 38.5 27.5 14.0 14.5 14.5 12.5 25.5
5 0.05 21.5 13.5 4.5 4.5 3.0 6.0 9.0 32.5 21.0 10.0 8.5 9.0 14.0 17.5 49.0 35.5 19.5 20.0 20.0 20.5 36.5
6 0.05 15.0 8.5 3.0 4.0 2.0 5.0 6.5 26.5 13.5 7.5 7.0 7.0 10.0 12.0 39.0 25.0 16.5 12.5 13.5 15.5 22.0
7 0.05 10.5 4.5 0.0 2.0 1.5 2.5 4.5 24.0 10.5 3.0 7.5 4.0 4.5 10.0 38.5 25.0 11.0 13.0 10.5 16.0 22.5
1 0.10 23.0 18.5 12.5 15.0 13.0 16.0 19.0 41.0 32.0 26.0 24.5 27.5 31.0 34.0 63.0 51.0 43.5 39.5 48.0 44.0 53.5
2 0.10 14.5 9.0 7.0 3.5 5.0 7.0 7.5 25.0 20.5 15.5 8.0 12.0 13.0 19.5 42.5 36.0 23.5 23.5 24.0 25.0 34.0
3 0.10 17.5 11.5 6.5 6.5 7.0 8.5 10.5 33.0 23.5 19.5 14.5 18.5 22.0 22.0 47.5 39.0 33.0 27.0 33.5 32.5 39.5
4 0.10 10.5 10.0 4.5 5.5 4.5 5.0 7.5 24.5 18.0 11.0 11.0 10.5 12.0 16.5 42.5 32.5 20.0 21.0 20.5 22.5 34.0
5 0.10 12.5 11.0 3.5 6.0 5.5 5.5 10.0 27.0 20.0 10.5 14.0 11.0 13.0 22.5 39.5 35.5 28.0 27.0 23.5 26.0 34.5
6 0.10 6.5 6.0 3.0 0.0 2.0 2.5 4.5 23.0 14.0 7.0 6.5 6.0 7.5 12.5 40.0 27.5 17.0 13.5 17.0 18.5 26.0
7 0.10 10.5 7.0 2.0 0.5 2.0 2.0 6.0 21.0 15.0 5.5 7.5 7.0 6.5 12.5 35.5 25.5 13.5 14.0 13.5 16.0 24.0
1 0.20 31.0 33.5 31.5 24.5 30.5 30.5 30.5 55.0 58.0 53.0 48.5 61.0 55.5 58.5 75.0 72.0 73.5 67.5 75.5 70.5 73.0
2 0.20 12.5 12.0 9.5 6.5 9.5 10.0 12.5 34.0 30.5 25.0 20.0 26.0 26.0 29.5 63.5 53.5 45.5 37.0 45.0 42.0 55.0
3 0.20 18.0 14.5 11.0 11.0 14.5 15.5 16.0 39.0 36.5 32.0 23.5 33.0 31.5 35.0 58.5 58.5 49.5 45.0 49.5 45.5 56.5
4 0.20 12.5 10.5 5.5 3.0 3.0 4.5 7.5 23.5 18.5 16.0 16.0 16.0 17.5 20.0 46.0 40.5 31.5 28.5 31.5 31.0 39.0
5 0.20 14.5 10.5 6.5 4.5 5.0 6.5 10.5 28.5 27.0 20.0 17.5 19.0 17.5 26.5 48.5 47.0 36.5 30.0 32.5 36.0 43.0
6 0.20 11.5 6.0 2.0 3.0 1.0 2.0 4.0 27.0 15.5 7.0 7.5 8.0 8.0 17.5 43.0 38.0 19.5 21.0 20.0 21.5 33.5
7 0.20 9.5 4.0 1.0 2.0 1.0 1.0 4.5 22.0 17.5 5.5 5.5 6.0 5.5 13.0 44.5 30.0 15.0 13.0 11.5 17.5 28.5
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test, T1 fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent MAF, WST weighted sum test, VTT variable threshold test,
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http://www.biomedcentral.com/1471-2105/14/177One major problem in testing multiple variants in the
same region of the genome is correlation due to linkage
disequilibrium (LD), although this may be less of an
issue for rare genetic variation. A permutation test can
account for type I error, but there is still a loss of power
as variants in strong LD with each other have a dispro-
portionate effect on the test statistic. To deal with this,
the RAML groups variants using a single link cluster ap-
proach, such that every variant in a group has a squared
correlation (r2) greater than a specified threshold with at
least one other variant in the same group. For each group
a proxy variant is generated, where the proxy is the max-
imum number of rare alleles for any variant in the group
(0, 1 or 2) carried by each subject. The default r2 threshold
is set to 0.9. This deals with perfectly correlated variants
whilst still being able to test most variants individually.
Restricting the parameter space to plausible values
should help to improve power. Therefore bounds for α,Table 4 Power (%) of RAML and SKAT methods to detect asso





1 0.05 47.5 31.5
2 0.05 39.5 24.0
3 0.05 43.0 29.5
4 0.05 33.5 22.5
5 0.05 39.5 25.5
6 0.05 33.5 21.5
7 0.05 37.5 30.5
1 0.10 40.0 34.5
2 0.10 36.0 29.0
3 0.10 32.5 28.5
4 0.10 31.0 22.0
5 0.10 33.5 25.0
6 0.10 32.5 21.5
7 0.10 31.5 23.0
1 0.20 47.5 50.0
2 0.20 26.5 34.5
3 0.20 41.0 40.5
4 0.20 26.0 26.0
5 0.20 35.0 26.5
6 0.20 27.5 24.5
7 0.20 23.5 19.0
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test
MAF, WST weighted sum test, VTT variable threshold test, EREC estimated regressionη and σ2 need to be defined as well as a definition of a
rare variant. We set the bound for specifying a variant as
rare as having a minor allele frequency of 0.04 or less.
We expect most variants will not be associated so we set
an upper limit for α of 0.2. As we want to be able to
model both strong protective and deleterious effects we
took the bounds for η to be from −5 to 5. We chose the
minimum value of σ2 to be 0.25. This represents the
minimum amount of variability we could expect about
the associated variant effects. Different choices of bounds
will do better in some scenarios and worse in others. Our
aim was to try to find a reasonable choice for likely effects
that are seen in genetic association studies.
Simulation testing
We simulated population data using phased haplotypes
from the 1000 Genome Project data (http://www.1000ge
nomes.org/). In order to determine the risk associated with
each haplotype the risk associated with each variant wasciation of rare variants under seven scenarios for
A1 in 4000 cases and 4000 controls
Threshold for significance
P < 0.01 P < 0.05
RAML SKAT-O RAML SKAT-O
61.0 44.0 73.5 58.5
53.5 36.0 64.5 49.0
61.5 43.0 70.5 55.0
49.5 29.0 59.5 42.5
57.0 39.5 62.0 51.5
43.0 29.5 57.0 41.5
51.0 38.0 56.5 45.5
58.0 50.0 76.0 66.0
50.5 42.5 65.5 58.0
53.0 42.5 67.5 58.0
45.5 35.5 59.0 48.5
55.0 39.5 71.0 59.5
48.5 31.5 62.0 48.5
44.0 35.0 60.5 46.5
71.0 67.5 83.5 81.0
49.0 46.0 69.5 68.0
59.5 52.5 74.0 67.0
44.5 40.0 67.5 55.5
51.5 44.5 70.0 64.5
45.5 37.0 62.5 55.0
46.0 35.5 63.0 59.5
, T1 fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent
coefficient test.
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defined below
1. β ~N(2σ, σ2)
2. 80 per cent of risk variants β ~N(2σ, σ2), 20 per cent
of risk variants β ~N(−2σ, σ2)
3. β ~N(σ, σ2)
4. 80 per cent of risk variants β ~N(σ, σ2), 20 per cent
of risk variants β ~N(−σ, σ2)
5. β ~N(σ/2, σ2)
6. 80 per cent of risk variants β ~N(σ/2, σ2), 20 per
cent of risk variants β ~N(−σ/2, σ2)
7. β ~N(0, σ2)
These scenarios are similar to the ones presented by
Lee et al. [8] with the main difference being that we
added some variability. The parameters were chosen to
give roughly the same power for each scenario.Table 5 Power (%) of RAML and SKAT methods to detect asso





1 0.05 78.5 14
2 0.05 69.5 8.5
3 0.05 67.5 9.5
4 0.05 61.5 6
5 0.05 68.5 8.5
6 0.05 61 12.5
7 0.05 65 9
1 0.10 75 14.5
2 0.10 61.5 13.5
3 0.10 59 9.5
4 0.10 58.5 7
5 0.10 65 9
6 0.10 61 9
7 0.10 66.5 5
1 0.20 83.5 19.5
2 0.20 63 9.5
3 0.20 66.5 7
4 0.20 53 8.5
5 0.20 70.5 10
6 0.20 59 11
7 0.20 61 5.5
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test
MAF, WST weighted sum test, VTT variable threshold test, EREC estimated regressionTwo haplotypes were selected at random for each in-
dividual. The overall risk associated with any pair of haplo-
types was calculated under a log-additive model by
summing the risks from each causal variant carried. An in-
dividual in the population was assigned as a case or con-
trol at random based on this risk and a disease prevalence
of 10 per cent. Two thousand cases and two thousand
controls were then selected randomly from the population.
For each risk distribution we tested three scenarios in
which 5%, 10% or 20% of variants were causal. The effect
was set as proportional to the log of the variant minor al-
lele frequency (p). The standard error (σ) varied under the
different distributions: For 5% of associated variants,
σ ¼ −0:04 log pð Þk
where k is 1 for distributions 1 and 2, 1.5 for distributions
3 and 4, 2 for distribution 5 and 6 and 2.5 for distributionciation of rare variants under seven scenarios for
A2 in 4000 cases and 4000 controls
Threshold for significance
P < 0.01 P < 0.05
RAML SKAT-O RAML SKAT-O
87.5 22 96 42.5
84 18 93 36
76.5 21 85 38
72 18.5 83.5 32.5
78.5 16 87 35.5
75.5 17.5 82 30.5
79 21.5 86.5 37.5
86 23 90.5 40.5
81.5 22 92.5 39.5
76 20 89 34
72 20.5 84 41
82 18.5 89.5 39
79 15.5 86.5 31
83.5 17 91 36
95 41 99 63.5
77 22.5 93.5 41
85.5 22.5 94 43.5
72.5 21 87 38.5
86 25.5 93 44
79 20.5 92 41.5
79.5 18.5 89.5 43.5
, T1 fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent
coefficient test.
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fect was 0.7 and 0.5 times this respectively.
We sampled haplotypes from three different regions of
the genome (TERT chr5: 1253287–1295162, BRCA2
chr13: 32889617–32973809, BRCA1 chr17: 41243452–
41277500) in order to evaluate the influence of different
local LD structure on the different tests. Two hundred
replicate data sets were simulated under each of the 21
different scenarios. We derived the power of each test as
the proportion of replicates for which the empirical sig-
nificance level achieved P < 0.05, P < 0.01 and P < 0.001.
We compared the RAML method to SKAT-O using the
default weights and the five methods included in the pro-
gram ScoreSeq. We also applied our tests to three dif-
ferent genes to evaluate the effects that varying genomic
architecture has on the relative efficacy of the methods.
In order to evaluate the power for a larger sample size
and slightly stronger effects we repeated the simulationsTable 6 Power (%) of RAML and SKAT methods to detect asso





1 0.05 75.5 53
2 0.05 72.5 42.5
3 0.05 68 42.5
4 0.05 62.5 35
5 0.05 57 36.5
6 0.05 57.5 35.5
7 0.05 58 34
1 0.10 84 62
2 0.10 68 47.5
3 0.10 68.5 50
4 0.10 56 37
5 0.10 66.5 42.5
6 0.10 57.5 38.5
7 0.10 63 41
1 0.20 90.5 87
2 0.20 70.5 57.5
3 0.20 74.5 65.5
4 0.20 66.5 54
5 0.20 72.5 58
6 0.20 57.5 41
7 0.20 60 41.5
Method with greatest power emboldened.
* See text for description of genetic architecture for each scenario.
RAML Rare admixture maximum likelihood, SKAT-O sequence kernel association test
MAF, WST weighted sum test, VTT variable threshold test, EREC estimated regressionfor four thousand cases and four thousand controls
across the same genomic regions with the effect of as-
sociated variants being 25 per cent larger. This data set
was used to compare the performance of RAML with
SKAT-O.
Results and discussion
There were 145 rare variants (MAF < 0.04) in BRCA1
(109 variants with MAF < 0.01, 27 with 0.01 <MAF <
0.02, 9 with 0.02 <MAF < 0.04), 274 rare variants in
BRCA2 (196, 22, 56) and 193 rare variants in TERT
(155, 23, 15). The power of the seven methods for 21
scenarios at the three thresholds for statistical sig-
nificance are shown in Tables 1, 2 and 3 for BRCA1,
BRCA2 and TERT respectively. Generally, power was
limited (< 50 per cent) for all methods across a wide
range of plausible scenarios for the underlying genetic
model. The RAML test had the greatest power for mostciation of rare variants under seven scenarios for
T in 4000 cases and 4000 controls
Threshold for significance
P < 0.01 P < 0.05
RAML SKAT-O RAML SKAT-O
87 66 90 80.5
85 66 90 78
79 57.5 88.5 73
76 50.5 86 64
74.5 50 84.5 61.5
71 52.5 84.5 67.5
73.5 48.5 83.5 64.5
90 79 93.5 89.5
80.5 66.5 87.5 77.5
81 65 89.5 78
70.5 53.5 80 68.5
80.5 59 90.5 78
79.5 53.5 88 70
83.5 61 91.5 73.5
96.5 96 99.5 98
84 75.5 93.5 85.5
89 79 96.5 89.5
80 72 92 84
86 72.5 92 87.5
76 61 90.5 80
74 59 86.5 76.5
, T1 fixed threshold test 1 per cent MAF, T5 fixed threshold test 5 per cent
coefficient test.
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RAML tended to have the greatest power for the scenarios
with a small proportion of associated variants, whereas
SKAT-O performed a little better for the scenarios with a
higher proportion of associated variants. Whether 100%
or 80% of variants are associated with effects in the same
direction did not change the relative efficacy of the two
methods.
Given the limited power of all the methods for the
analysis of 2,000 cases and 2,000 controls, we repeated
the evaluation of RAML and SKAT-O using data simu-
lated for 4,000 cases and 4,000 controls across the same
genomic regions. There were 145 rare variants (MAF
< 0.04) in BRCA1 (109 variants with MAF < 0.01, 27
with 0.01 <MAF < 0.02, 9 with 0.02 <MAF < 0.04), 274
rare variants in BRCA2 (196, 22, 56) and 193 rare vari-
ants in TERT (155, 23, 15). The power of the two
methods for 21 scenarios at the three thresholds for stat-
istical significance are shown in Tables 4, 5 and 6 for
BRCA1, BRCA2 and TERT respectively. As expected, the
power of the both methods is improved. The RAML
method was still more powerful than SKAT-O under
most scenarios, but the difference was greater than for
the smaller sample sizes.
The apparent difference between RAML and SKAT-O
for the BRCA1 and the other two regions is related to
the fact that SKAT-O does not use a fixed threshold for
the minor allele frequency, but uses a weighting function
based on the minor allele frequency [7]. Thus the method
is sensitive to the number of variants around the threshold
MAF of interest. There were relatively fewer variants with
a MAF just above 4 per cent in BRCA1 than in the other
two genes.
Conclusion
We have described a new method for association testing
of multiple rare variants that makes no assumptions
about the proportion of variants that are associated with
the phenotype of interest or the magnitude and direction
of their effect. The method is flexible and can be applied
to both dichotomous and quantitative traits and allows
for the inclusion of covariates in the underlying regression
model. We have compared the performance of RAML
with six other similar methods using data simulated under
21 plausible scenarios for the underlying genetic model of
association. Under most of these scenarios, RAML was
found to have the greatest power, although SKAT-O per-
formed better under some circumstances.
Genome-wide association studies have been very suc-
cessful in identifying common alleles associated with
many disease and physiological traits. However, these al-
leles explain a small fraction of the genetic component
of the variance for most traits. It is very likely that rare
variants will contribute to some of the so-called missingheritability. A systematic search for disease associated
rare variants has been made possible by the availability
of high-throughput, affordable sequencing technologies
and the development of genotyping arrays that include
hundreds of thousands of rare variants. Given that the
underlying genetic model for association between rare
genetic variants and disease related phenotypes is not
known – effect allele frequency, effect size and propor-
tion of associated variants - it is not possible to provide
a definitive guide to the situations in which RAML
should be preferred to SKAT-O or other methods. Until
empirical evidence emerges for association of multiple
rare variants across a genomic region it would seem rea-
sonable to use multiple methods for burden testing in-
cluding both RAML and SKAT-O.Appendix
The AML and RAML software are available from http://
ccge.medschl.cam.ac.uk/software/.
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